Vincerx Pharma, Inc. (VINC)
Market: NASD |
Currency: USD
Address: 260 Sheridan Avenue
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California.
Show more
📈 Vincerx Pharma, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
-
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
25-50%
-
Revenue Growth Range (1Y):
-
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2025 |
- |
$0.050000 |
- |
2025-01-28 |
- |
Stock split |
|
Total Amount for 2025: $0.050000 |
📅 Earnings & EPS History for Vincerx Pharma, Inc.
| Date | Reported EPS |
|---|
| 2026-03-25 (estimated upcoming) | - |
| 2025-11-10 (estimated upcoming) | - |
| 2025-11-09 (estimated upcoming) | - |
| 2025-08-06 (estimated upcoming) | - |
| 2025-08-05 (estimated upcoming) | - |
| 2025-05-12 | - |
| 2025-05-11 | - |
| 2025-03-27 | -4.2 |
| 2025-03-26 | - |
| 2024-11-12 | -0.17 |
| 2024-08-08 | -0.05 |
| 2024-08-07 | -0.05 |
| 2024-05-14 | -0.58 |
| 2024-05-13 | -0.58 |
| 2024-03-29 | -0.23 |
| 2024-03-28 | -0.23 |
| 2023-11-14 | -0.46 |
| 2023-11-13 | -0.46 |
| 2023-08-07 | -0.52 |
| 2023-08-06 | -0.52 |
| 2023-05-11 | -0.68 |
| 2023-05-10 | -0.68 |
| 2023-03-28 | -0.65 |
| 2023-03-27 | -0.65 |
| 2022-11-10 | -0.8 |
| 2022-11-09 | -0.8 |
| 2022-08-11 | -0.88 |
| 2022-08-10 | -0.88 |
| 2022-05-12 | -0.79 |
| 2022-05-11 | -0.79 |
| 2022-03-29 | -0.31 |
| 2022-03-28 | -0.31 |
| 2021-11-12 | -1.39 |
| 2021-11-11 | -1.39 |
| 2021-08-12 | -0.12 |
| 2021-08-11 | -0.12 |
| 2021-05-17 | -0.46 |
| 2021-05-16 | -0.46 |
| 2021-03-22 | - |
| 2021-03-21 | - |
| 2020-12-07 | - |
| 2020-12-06 | - |
| 2020-10-08 | - |
| 2020-10-07 | - |
📰 Related News & Research
No related articles found for "vincerx pharma".
